GlaxoSmithKline Pakistan (KAR:GLAXO) Market Cap: ₨117,913 Mil (As of Jul. 01, 2026)


KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
92 GF Score
Price ₨370.25
GF Value ₨324.26
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan Market Cap?

GlaxoSmithKline Pakistan KAR:GLAXO +1.66% 92 Market Cap is ₨117,913 Mil as of Jul. 01, 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,022 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 59.3% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). GlaxoSmithKline Pakistan's share price for the quarter that ended in Mar. 2026 was ₨314.93. GlaxoSmithKline Pakistan's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 318 Mil. Therefore, GlaxoSmithKline Pakistan's market cap for the quarter that ended in Mar. 2026 was ₨100,295 Mil.

GlaxoSmithKline Pakistan's quarterly market cap declined from Sep. 2025 (₨142,192 Mil) to Dec. 2025 (₨124,132 Mil) and declined from Dec. 2025 (₨124,132 Mil) to Mar. 2026 (₨100,295 Mil).

GlaxoSmithKline Pakistan's annual market cap increased from Dec. 2023 (₨26,430 Mil) to Dec. 2024 (₨126,403 Mil) but then declined from Dec. 2024 (₨126,403 Mil) to Dec. 2025 (₨124,132 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GlaxoSmithKline Pakistan's Enterprise Value for Today is ₨108,358 Mil.


GlaxoSmithKline Pakistan  (KAR:GLAXO) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


GlaxoSmithKline Pakistan Market Cap Related Terms


GlaxoSmithKline Pakistan Market Cap Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan Market Cap Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43,473.93 27,951.85 26,429.58 126,402.74 124,132.07

GlaxoSmithKline Pakistan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133,256.15 124,431.43 142,192.33 124,132.07 100,294.81

KAR:GLAXO vs ZTS, UTHR, VTRS: Market Cap Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pakistan Market Cap vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Market Cap distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's Market Cap falls into.


KAR:GLAXO
92GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pakistan Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

GlaxoSmithKline Pakistan's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=₨389.78*318.467
=₨124,132

GlaxoSmithKline Pakistan's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=₨314.93*318.467
=₨100,295

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of ₨117,913 Mil mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Market Cap of ₨117,913 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GlaxoSmithKline Pakistan and its competitors. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #416 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 40.7%.
Is GlaxoSmithKline Pakistan's Market Cap too high?
GlaxoSmithKline Pakistan's current Market Cap is ₨117,913 Mil. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #416 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #416 out of 1022 companies for Market Cap. This puts GlaxoSmithKline Pakistan in the upper half of its industry. The industry median Market Cap is 210.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.16, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Market Cap is ₨117,913 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current Market Cap is ₨117,913 Mil. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Market Cap is ₨117,913 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26. GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.

Key valuation signals for KAR:GLAXO:

  • Market Cap: ₨117,913 Mil
  • GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score

Get the complete analysis for KAR:GLAXO

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨370.25
Price
₨324.26
GF Value